- Home
- AMPX vs UPB Comparison
AMPX vs UPB Comparison
Compare AMPX & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPX
- UPB
- Stock Information
- Founded
- AMPX 2008
- UPB 2021
- Country
- AMPX United States
- UPB United States
- Employees
- AMPX N/A
- UPB N/A
- Industry
- AMPX Industrial Machinery/Components
- UPB
- Sector
- AMPX Miscellaneous
- UPB
- Exchange
- AMPX Nasdaq
- UPB NYSE
- Market Cap
- AMPX 514.7M
- UPB 521.3M
- IPO Year
- AMPX N/A
- UPB 2024
- Fundamental
- Price
- AMPX $4.68
- UPB $11.20
- Analyst Decision
- AMPX Strong Buy
- UPB Strong Buy
- Analyst Count
- AMPX 7
- UPB 4
- Target Price
- AMPX $8.71
- UPB $56.50
- AVG Volume (30 Days)
- AMPX 5.9M
- UPB 500.3K
- Earning Date
- AMPX 08-07-2025
- UPB 08-14-2025
- Dividend Yield
- AMPX N/A
- UPB N/A
- EPS Growth
- AMPX N/A
- UPB N/A
- EPS
- AMPX N/A
- UPB N/A
- Revenue
- AMPX $33,115,000.00
- UPB $2,296,000.00
- Revenue This Year
- AMPX $167.22
- UPB N/A
- Revenue Next Year
- AMPX $208.02
- UPB N/A
- P/E Ratio
- AMPX N/A
- UPB N/A
- Revenue Growth
- AMPX 209.20
- UPB N/A
- 52 Week Low
- AMPX $0.61
- UPB $5.14
- 52 Week High
- AMPX $4.83
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- AMPX 68.15
- UPB N/A
- Support Level
- AMPX $3.80
- UPB N/A
- Resistance Level
- AMPX $4.35
- UPB N/A
- Average True Range (ATR)
- AMPX 0.36
- UPB 0.00
- MACD
- AMPX 0.05
- UPB 0.00
- Stochastic Oscillator
- AMPX 89.29
- UPB 0.00
About AMPX Amprius Technologies Inc.
Amprius Technologies Inc is engaged in the production of silicon anodes for high-energy-density lithium-ion batteries. The company develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (EV) and light electric vehicle (LEV) industries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.